Form 4: Intra-Cellular Therapies Director Van Nostrand Reports Stock Transaction

Director Robert L. Van Nostrand of Intra-Cellular Therapies, Inc. reports acquiring 79 shares of common stock at $69.20 on March 31, 2024.

Summary

• On March 31, 2024, Robert L. Van Nostrand, a director of Intra-Cellular Therapies, Inc. (ITCI), acquired 79 shares of common stock.
• The transaction was a purchase, with the shares acquired at a price of $69.20 per share.
• Following the transaction, Van Nostrand directly owns 9,690 shares of ITCI common stock.

Sentiment

Score: 5

Explanation: This is a routine disclosure of a stock transaction by a company director. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their trading activities. They are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transaction provides shareholders with information about the trading activity of a company director, which can influence investor sentiment.

Key Dates